Asset Details
Do you wish to reserve the book?
Novartis Reply to the ATMOSPHERE Data Monitoring Committee
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Novartis Reply to the ATMOSPHERE Data Monitoring Committee
Do you wish to request the book?
Novartis Reply to the ATMOSPHERE Data Monitoring Committee
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Novartis Reply to the ATMOSPHERE Data Monitoring Committee
2016
Overview
To the Editor:
The Sounding Board article by Swedberg and colleagues,
1
now published in the
Journal,
describes the experience of the data monitoring committee of the Aliskiren Trial to Minimize Outcomes in Patients with Heart Failure (ATMOSPHERE) as data from other trials of aliskiren raised questions regarding a possible risk to participants in ATMOSPHERE.
2
Novartis, as the sponsor of ATMOSPHERE, had engaged the independent data monitoring committee, which was composed of respected experts, to oversee the participants’ safety in this trial through periodic reviews of unblinded safety and efficacy data. During the course of the trial, the data monitoring committee, . . .
Publisher
Massachusetts Medical Society
